Back to Journals » Lung Cancer: Targets and Therapy

Lung Cancer: Targets and Therapy

ISSN: 1179-2728


Journal Articles:

- 166 records -

Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer

Deck J, Hartley M, Akhter M, Wang D, Bogart JA, Mix MD

Lung Cancer: Targets and Therapy 2023, 14:47-55

Published Date: 19 May 2023

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code

Brazel D, Kim J, Ou SI

Lung Cancer: Targets and Therapy 2023, 14:31-39

Published Date: 20 April 2023

CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma Code

Zhang SS, Lee A, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:27-30

Published Date: 19 April 2023

Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review

Nigro MC, Marchese PV, Deiana C, Casadio C, Galvani L, Di Federico A, De Giglio A

Lung Cancer: Targets and Therapy 2023, 14:11-25

Published Date: 3 February 2023

Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Brazel D, Ou SI, Nagasaka M

Lung Cancer: Targets and Therapy 2023, 14:1-9

Published Date: 5 January 2023

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib

Brazel D, Arter Z, Nagasaka M

Lung Cancer: Targets and Therapy 2022, 13:75-80

Published Date: 10 November 2022

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy

Carpentier J, Pavlyk I, Mukherjee U, Hall PE, Szlosarek PW

Lung Cancer: Targets and Therapy 2022, 13:53-66

Published Date: 5 September 2022

An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma

Davis A, Ke H, Kao S, Pavlakis N

Lung Cancer: Targets and Therapy 2022, 13:1-12

Published Date: 2 March 2022

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond

Fitzpatrick O, Naidoo J

Lung Cancer: Targets and Therapy 2021, 12:123-131

Published Date: 2 November 2021

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer

Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, Sukari A, Nagasaka M

Lung Cancer: Targets and Therapy 2021, 12:103-114

Published Date: 7 October 2021

An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece

Mountzios G, Lampaki S, Koliou GA, Vozikis A, Kontogiorgos I, Papantoniou P, Koufaki MI, Res E, Boutis A, Christopoulou A, Pastelli N, Grivas A, Aravantinos G, Lalla E, Oikonomopoulos G, Koumarianou A, Spyratos D, Bafaloukos Snr D, Rigakos G, Papakotoulas P, Fountzilas G, Linardou H

Lung Cancer: Targets and Therapy 2021, 12:93-102

Published Date: 30 August 2021

An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer

Peled N, Fuchs V, Kestenbaum EH, Oscar E, Bitran R

Lung Cancer: Targets and Therapy 2021, 12:81-92

Published Date: 16 August 2021

Targeting AXL in NSCLC

Zaman A, Bivona TG

Lung Cancer: Targets and Therapy 2021, 12:67-79

Published Date: 10 August 2021

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib

Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW

Lung Cancer: Targets and Therapy 2021, 12:11-20

Published Date: 18 March 2021

Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study

Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B

Lung Cancer: Targets and Therapy 2020, 11:113-121

Published Date: 18 December 2020

Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer

Nagata I, Ogino T, Arimura T, Yoshiura T

Lung Cancer: Targets and Therapy 2020, 11:105-111

Published Date: 9 October 2020

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J

Lung Cancer: Targets and Therapy 2020, 11:59-71

Published Date: 7 September 2020

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T

Lung Cancer: Targets and Therapy 2020, 11:53-57

Published Date: 12 July 2020

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors

Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM

Lung Cancer: Targets and Therapy 2020, 11:33-39

Published Date: 17 April 2020

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients

Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K

Lung Cancer: Targets and Therapy 2020, 11:19-25

Published Date: 24 February 2020

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases

Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI

Lung Cancer: Targets and Therapy 2020, 11:13-18

Published Date: 14 January 2020

The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer

Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K

Lung Cancer: Targets and Therapy 2020, 11:1-11

Published Date: 8 January 2020

Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer

Mix M, Tanny S, Nsouli T, Alden R, Chaudhari R, Kincaid R, Rosenbaum PF, Bogart JA, Aridgides P

Lung Cancer: Targets and Therapy 2019, 10:151-159

Published Date: 20 December 2019

Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma

Baldovini C, Rossi G, Ciarrocchi A

Lung Cancer: Targets and Therapy 2019, 10:131-149

Published Date: 5 December 2019

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI

Lung Cancer: Targets and Therapy 2019, 10:125-130

Published Date: 13 November 2019

Landscape on CT screening for lung cancer in Asia

Triphuridet N, Henschke C

Lung Cancer: Targets and Therapy 2019, 10:107-124

Published Date: 30 September 2019

A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors

Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A

Lung Cancer: Targets and Therapy 2019, 10:95-105

Published Date: 12 September 2019

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR

Lung Cancer: Targets and Therapy 2019, 10:81-86

Published Date: 15 August 2019

Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients

Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A

Lung Cancer: Targets and Therapy 2019, 10:57-66

Published Date: 17 June 2019

More articles